Vanda Pharmaceuticals (VNDA): יחס שווי שוק לרווח וקצב צמיחה

Vanda Pharmaceuticals (VNDA) price action is driven by patent disputes and insurance limits for sleep medications. On GURU.Markets, the PEG ratio demonstrates volatility, where the value of 0.00 corresponds to the current metric. Stable margins in the schizophrenia niche are complemented by an academic approach to hiring neurobiologists, ensuring the company's sustainable development.

This indicator is calculated by dividing the P/E ratio by the annual earnings growth rate, allowing for an objective valuation of the business relative to its expansion. By analyzing the correlation between P/E and growth rates, an investor can determine the undervaluation of Vanda Pharmaceuticals (VNDA), where the potential for FDA approval of new indications for CNS and sleep medications could create a sharp imbalance between the market price and actual earnings dynamics.